首页> 外文OA文献 >Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease
【2h】

Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease

机译:重组VIIa因子成功治疗患有获得性von Willebrand病的患者的抗治疗性严重出血

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We describe an elderly man who presented with life-threatening hematuria and gastrointestinal bleeding caused by acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance (MGUS). Standard therapy with desmopressin, von Willebrand factor-containing factor VIII concentrate, tranexamic acid, and immunoglobulin failed to achieve adequate hemostasis. However, treatment with recombinant activated factor VII (rFVIIa) arrested the bleeding completely. Since acquired von Willebrand disease can lead to life-threatening hemorrhage, clinicians should consider rFVIIa as an effective treatment option if standard therapy fails
机译:我们描述了一位老人,他患有与获得性意义不明的单克隆丙种球蛋白病(MGUS)相关的后天性von Willebrand病引起的致命性血尿和胃肠道出血。用去氨加压素,含von Willebrand因子的VIII因子浓缩液,氨甲环酸和免疫球蛋白的标准疗法未能达到足够的止血效果。但是,用重组活化因子VII(rFVIIa)治疗可完全止血。由于后天性von Willebrand病可导致危及生命的出血,因此,如果标准治疗失败,临床医生应将rFVIIa视为有效的治疗选择

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号